Robert Dreicer, MD, MS, from the Taussig Cancer Institute at the Cleveland Clinic, describes potential combination therapies currently being considered as treatments for men with prostate cancer.
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, describes potential combination therapies currently being considered as treatments for men with prostate cancer.
Currently, Dreicer notes, a phase I/II trial is investigating the combination of the androgen receptor (AR) antagonist enzalutamide and the lyase inhibitor abiraterone acetate. This combination is supported by preclinical evidence that suggest synergy between these agents.
Dreicer notes that researchers are interested in the combination of AR antagonists with novel agents, such as sipuleucel-T (Provenge) and radium-223. In general, the agents approved to treat prostate cancer have varying mechanisms of action and favorable toxicity profiles, which provides an abundance of potential for novel combinations.